infections (URIs) to lower respiratory tract infections (LRIs) with subsequent bacterial co-infections in these patients than in the general population. [5] [6] [7] [8] Also, immunocompromised patients experience persistent viral shedding, need hospitalization and mechanical ventilation, and have high mortality rates following acquisition of influenza infections. [9] [10] [11] [12] Researchers have shown that delay from onset of influenza symptoms to seeking medical care and initiation of antiviral therapy is correlated with poor outcomes, mainly in HCT recipients. [2] [3] [4] Influenza is increasingly recognized as a serious infection with fatal consequences in patients with HMs. However, only few studies focusing on influenza in cancer patients have been published. [12] [13] [14] [15] Most of these published studies included few patients with influenza during the H1N1 pandemic in the 2009 and 2010 influenza seasons, 8, 10, 12, 16, 17 and few of them described the clinical presentations, risk factors, and outcomes during the pandemic and postpandemic seasons in this vulnerable patient population.
| OBJECTIVES
Therefore, we conducted this retrospective study described herein to centers approved the study, informed consent was waived, no patient contacts were made, and patient confidentiality was protected.
Collected data included demographics, comorbidities, underlying malignancies, oncological treatment, immunosuppressive therapy, clinical presentations, radiological and laboratory investigation results, concurrent co-infections, treatments, and outcomes. All patients were observed until resolution of all signs and symptoms of infection or death.
| Definitions
A case of influenza was defined as a patient with an HM (leukemia, lymphoma, or multiple myeloma) having acute respiratory illness and influenza infection confirmed via viral culture, direct fluorescent antigen testing (DFA), and/or real-time polymerase chain reaction (PCR) assay. The infection was classified as i) community-acquired if the onset of symptoms occurred before or within the first 2 days after hospital admission or ii) nosocomial if the symptoms developed any time after that during hospitalization. URI was characterized by onset of rhinorrhea, nasal/sinus congestion, and pharyngitis or cough with or without expectoration, and its diagnosis was confirmed using any of the tests listed above and by a normal or unchanged chest radiograph or computed tomography scan at the time of diagnosis. LRI was characterized by new or changing pulmonary infiltrates suggestive of viral etiology on chest imaging and confirmed via examination of respiratory specimens, including nasal washes, endotracheal tube aspirates, sputum specimens, and bronchoalveolar lavage fluid specimens. A concurrent infection was considered when another organism was isolated from a patient within 3 days after diagnosis of influenza.
Neutropenia was defined as an absolute neutrophil count less than 500 cells/mL, and lymphopenia was defined as an absolute lymphocyte count less than 200 cells/mL. Obesity was defined as a body mass index (BMI) of at least 30 kg/m 2 in adults and a BMI percentile of at least 95% in children up to 18 years old.
| Statistical analysis
After checking patient data for accuracy and consistency, the clinical presentations and outcomes of influenza infection in the study patients at the two centers were compared for categorical variables using a chi-square test or the Fisher exact test and for continuous variables using the Student t-test or Wilcoxon rank sum test. Using multivariable logistic regression modeling, differences in the characteristics of the patients with LRIs and of those with URIs were identified.
Risk factors associated with mortality 60 days after influenza diagnosis also were identified using multivariable logistic regression analysis. The probability of death in influenza cases stratified by type of malignancy and development of LRI in the two centers was compared using Kaplan-Meier failure curves. A two-sided P value of 0.05 was considered statistically significant for all analyses, which were performed using the Stata software program (version 13; StataCorp, College Station, TX).
| RESULTS
We identified a total of 190 patients with laboratory-confirmed influenza in the two cancer centers (135 at center 1 and 55 at center 2) during the study period. Their median age was 49 years (range, 1-88 years), and 120 of them (63%) were male. The majority of the patients had leukemia (54%) and an active or refractory underlying malignancy (76%). Distribution of age, sex, and type of underlying malignancy did not differ between the two centers. However, the patient ethnicities were more diverse in center 1 than in center 2 (P < 0.001). When compared with the patients in center 1, those in center 2 were sicker:
89% had an active or refractory malignancy at the time of influenza diagnosis (P = 0.008), 27% had an elevated creatinine level (P = 0.03), and 62% had an albumin level less than 3.5 mg/dL (P < 0.001). In addition, we observed more patients in center 2 with LRIs (40% vs 27%; P = 0.089) or hypoxia at influenza diagnosis (75% vs 7%; P < 0.001) ( Table 1) .
VILAR-COMPTE ET AL. Clinical characteristics of and influenza outcomes in the patients at both centers are listed in Table 1 . The majority of the influenza infections (131 [69%]) were URIs at diagnosis. However, more patients at center 2 experienced progression from URI to LRI (42% vs 7%; P < 0.001), were hospitalized (85% vs 56%; P < 0.001), and needed mechanical ventilation (35% vs 6%; P < 0.001) as per predictors of mortality when adjusted for the differences between the patients in the two cancer centers. The average time from onset of symptoms to diagnosis of influenza was 3 days (range, 0-21 days), and we did not observe any significant differences in this duration between patients who died and those who recovered from their infections in either center.
Kaplan-Meier curves showed that the 60-day all-cause mortality rate was significantly higher in patients in center 2 than in those in center 1 (P = 0.002) (Figure 2 ) . However, after stratification for type of malignancy the mortality rates in center 2 were similar for all types of HM ( Figure 3) . Similarly, we observed a significantly higher allcause mortality rate in patients with LRIs in center 2 than in those in center 1 (P = 0.002 [log-rank test]). The mortality rates in patients without LRIs did not differ significantly between the two centers, though ( Figure 2 ). Compared with the patients in the American center, those in Mexico were sicker (having active cancer, decreased albumin level, elevated creatinine level, hypoxia at diagnosis) and had markedly higher rates of LRI and mortality. We did not identify any differences in outcome between the two centers with respect to receipt of early antiviral therapy (within 24 h of influenza diagnosis). To our knowledge, this is one of the largest studies of HM patients with influenza in two cancer centers.
Besides the expected differences in ethnicity of HM patients between the two cancer centers, we observed other significant differences, mainly in their clinical characteristics, such as a higher rate of active or refractory HM and use of corticosteroids, higher creatinine levels, and lower serum albumin at the time of influenza diagnosis in center 2. These characteristics are surrogate markers for advanced underlying malignancy and subsequent increased immunosuppression, indicating that patients in center 2 were much sicker than those in center 1. Furthermore, physicians diagnosed influenza at later stages in patients in center 2, and they had worse outcomes than did patients in center 1.
Patients with HMs have a wide range of influenza-associated LRI rates (21-80%). 8, 11, 13 In our cohort, the observed rate was on the higher end of the spectrum, with a total of 80 (42%) patients having LRIs. Patients with leukemia, a decreased albumin level, hypoxia at diagnosis, a respiratory co-infection or receiving corticosteroids were at increased risk for LRI. Of these risk factors, lymphocytopenia and corticosteroid use have been related to severe influenza and poor outcomes in other studies of HM patients and HCT recipients. 8, 12, 14, 15 Authors also reported that hypoalbuminemia is a risk factor for pneumonia in a single-center cohort of patients with hematological disease having influenza. 13 Respiratory co-infections are very common (20-40%) in immunocompromised cancer patients with influenza and are especially troublesome if the co-infection is affecting the lungs. 1, 4, 5 We observed that 28 (15%) of our patients had respiratory coinfections, which was associated with increased rates of poor outcome (LRI and death). We did not observe a correlation between BMI and poor outcome following influenza infection.
After adjusting for factors such as elevated creatinine level, hypoxia at diagnosis, and respiratory co-infection in multivariable analyses, the difference in mortality rate between the two centers was not significant. In a previous study, investigators analyzed these risk factors in HCT recipients with influenza. 17 Authors reported that other factors, such as nosocomial infection, profound lymphocytopenia, neutropenia, and delayed antiviral treatment, increased the risk of Nevertheless, all HM patients diagnosed with influenza are recommended to receive adequate antiviral therapy as early as possible, preferably within 48 h after symptom onset, as it may prevent severe complications of influenza in immunocompromised patients. 2, 4 Our study has few limitations. First, this was a retrospective study of data collected from laboratory reports (DFA or culture in center 1 and PCR or culture in center 2) and medical records in centers in two different countries, which may have led to some information bias. However, we assumed this bias to be minimal, as both institutions are cancer referral centers with standardized center-specific management protocols (oseltamivir-based regimens)
for patients with influenza. Furthermore, trained infectious disease physicians collected the data using a common data collection form, and they performed rigorous data-quality checks, resolving discrepancies in the data via mutual discussion. Not all of the outpatients with influenza-like illness (ILI) at center 2 were screened for influenza, which is a possible source of selection bias. This 
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